Revenue
5Y CAGR +19.2%5Y CAGR +19.2%No quarters filed for this figure.
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Bar = where today’s multiple sits in NVO’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).
No quarters filed for this figure.
No quarters filed for this figure.
No quarters filed for this figure.
FY25: operating cash flow $18B, capex −$9.1B
No quarters filed for this figure.
No quarters filed for this figure.
No quarters filed for this figure.
Novo Nordisk A/S Sponsored ADR is a healthcare company focused on discovering, developing, manufacturing, and marketing pharmaceutical products. The company’s current business is organized around diabetes and obesity care, where it offers treatments and related devices for chronic metabolic conditions, and rare disease, where it serves patients with specialized therapies for blood disorders and endocrine disorders. Novo Nordisk A/S Sponsored ADR works with patients, healthcare professionals, and care providers across global markets, supplying medicines used in long-term disease management. As a sponsored ADR, it gives investors a U.S.-traded representation of the company’s underlying shares while reflecting the performance of its international healthcare operations. The company is headquartered in Bagsværd, Denmark, and remains a major participant in the global pharmaceutical industry through its focus on chronic disease treatment and specialty care.
Bagsvaerd, Denmark·66,700 employees·Drug Manufacturers - General·novonordisk.com·As of Oct 28, 2026
No earnings release, press release or insider trade outside a 10b5-1 plan in the last 120 days.
All filings and insider trades →13 of the 193 ETFs ChartRow carries live hold NVO. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).
| Fund | Name | Filed weight |
|---|---|---|
| VIGI | Vanguard International Dividend Appreciation ETF | 2.6% |
| VGK | Vanguard FTSE Europe ETF | 0.9% |
| VYMI | Vanguard International High Dividend Yield ETF | 0.8% |
| EFA | iShares MSCI EAFE ETF | 0.7% |
| VEA | Vanguard FTSE Developed Markets ETF | 0.5% |
| VEU | Vanguard FTSE All-World ex-US ETF | 0.4% |
| VXUS | Vanguard Total International Stock ETF | 0.3% |
| URTH | iShares MSCI World ETF | 0.2% |
| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +24.07% | +0.61% |
| JNJ | Johnson & Johnson | +7.92% | +3.81% |
| ABBV | AbbVie Inc. | +12.18% | +3.09% |
| MRK | Merck & Co. Inc. | +4.20% | +3.93% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | +10.08% | +1.22% |
| NVS | Novartis AG | +17.01% | +3.59% |
| TMO | Thermo Fisher Scientific Inc. | +7.84% | +1.12% |
| AMGN | Amgen Inc. | +18.69% | +3.71% |